Home › Funds › TENOR CAPITAL MANAGEMENT Co., L.P. › BMRN
TENOR CAPITAL MANAGEMENT Co., L.P. position in BMRN
BIOMARIN PHARMACEUTICAL INC COM · Health Care
TENOR CAPITAL MANAGEMENT Co., L.P. reported holding 111,500,000 shares of BMRN (BIOMARIN PHARMACEUTICAL INC COM) in its Q2 2026 13F filing — a position valued at US$108.9M, representing 2.02% of its reported portfolio and ranking #7 among its reported holdings. TENOR CAPITAL MANAGEMENT Co., L.P. has disclosed BMRN holdings in 8 of the last 11 reported quarters, going back to Q4 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How TENOR CAPITAL MANAGEMENT Co., L.P.'s BMRN position evolved
TENOR CAPITAL MANAGEMENT Co., L.P. first disclosed a stake in BMRN in Q4 2023 at 2,932,000 shares (US$2.90B). The position peaked in Q2 2024 at 23,693,000 shares, worth US$23.65B. Across 8 filings, TENOR CAPITAL MANAGEMENT Co., L.P. increased the stake 4 time(s), trimmed it 1 time(s) and left it unchanged 1 time(s). The most recent filing (Q2 2026) shows 111,500,000 shares valued at US$108.9M. Notable position changes include a 639% increase in Q1 2024 (shares fell 6% over the following quarter), a 32% increase in Q3 2025 (shares rose 10% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2023 | 2.93M | $2.90B | New |
| Q1 2024 | 21.66M | $21.33B | Add |
| Q2 2024 | 23.69M | $23.65B | Add |
| Q2 2025 | 77.58M | $73.28M | New |
| Q3 2025 | 102.08M | $97.51M | Add |
| Q4 2025 | 116.50M | $112.24M | Add |
| Q1 2026 | 111.50M | $108.12M | Reduce |
| Q2 2026 | 111.50M | $108.89M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About BMRN and 13F data
BMRN (BIOMARIN PHARMACEUTICAL INC COM) is a Health Care company. 26 other funds we track also report a position in BMRN — the largest reported positions include PRIMECAP MANAGEMENT CO/CA/ (US$812.0M), Viking Global Investors (US$435.8M), VIKING GLOBAL INVESTORS LP (US$435.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding BMRN
- PRIMECAP MANAGEMENT CO/CA/ 14.19M sh · $811.96M · Q2 2026
- Viking Global Investors 7.62M sh · $435.82M · Q2 2026
- VIKING GLOBAL INVESTORS LP 7.62M sh · $435.82M · Q2 2026
- Vestal Point Capital, LP 6.03M sh · $344.75M · Q2 2026
- Deep Track Capital, LP 3.31M sh · $189.25M · Q2 2026
More on TENOR CAPITAL MANAGEMENT Co., L.P.
FAQ
How long has TENOR CAPITAL MANAGEMENT Co., L.P. held BMRN?
TENOR CAPITAL MANAGEMENT Co., L.P. has disclosed BMRN holdings in 8 of the last 11 reported quarters, going back to Q4 2023.
What is TENOR CAPITAL MANAGEMENT Co., L.P.'s current position in BMRN?
As of Q2 2026, TENOR CAPITAL MANAGEMENT Co., L.P. holds 111.50M shares of BMRN (BIOMARIN PHARMACEUTICAL INC COM), valued at $108.89M, representing 2.02% of its reported portfolio and ranking #7.
Has TENOR CAPITAL MANAGEMENT Co., L.P. been buying or selling BMRN?
In the latest 13F filing (Q2 2026), TENOR CAPITAL MANAGEMENT Co., L.P. held unchanged its position in BMRN. The position peaked in Q2 2024 at 23.69M shares.
Which other funds hold BMRN?
Other major institutional holders of BMRN include PRIMECAP MANAGEMENT CO/CA/, Viking Global Investors, VIKING GLOBAL INVESTORS LP, among 26 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.